The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Preoperative chemotherapy for women with operable breast cancer
Open accessAbstract
BACKGROUND: Currently, preoperative chemotherapy is the standard of care in locally advanced breast cancer to achieve local tumour downsizing in order to make surgery possible. Since the early 1980s, the role of preoperative chemotherapy in early stage (or operable) breast cancer has been the subject of study. Potential advantages are early introduction of systemic therapy, determination of chemosensitivity, reduction of tumour volume and downstaging of surgical requirement. Concerns exist about local control after downsized surgery and the delay of local treatment in patients with tumours resistant to chemotherapy. OBJECTIVES: To assess the effectiveness of preoperative chemotherapy in women with operable breast cancer when compared to postoperative chemotherapy. SEARCH STRATEGY: The Specialised Register maintained by the Editorial Base of the Cochrane Breast Cancer Group was searched on 4th of August 2005. SELECTION CRITERIA: Randomised trials comparing preoperative chemotherapy with postoperative in women with operable breast cancer. DATA COLLECTION AND ANALYSIS: Studies were assessed for eligibility and quality, and data were extracted by two independent review authors. Hazard ratios were derived for time-to-event outcomes directly or indirectly using the methods described by Parmar. Relative risks were derived for dichotomous outcomes. Meta-analyses were performed using fixed effect model. MAIN RESULTS: We identified 14 eligible studies which randomised a total of 5,500 women. Median follow-up ranged from 18 to 124 months. Eight studies described a satisfactory method of randomisation.Data, based on 1139 estimated deaths in 4620 women available for analysis, show equivalent overall survival rates with a HR of 0.98 (95% CI, 0.87 to 1.09; p, 0.67; no heterogeneity). Preoperative chemotherapy increases breast conservation rates, yet at the associated cost of increased loco regional recurrence rates. However, this rate was not increased as long as surgery remains part of the treatment even after complete tumour regression (HR, 1.12; 95% CI, 0.92 to 1.37; p, 0.25; no heterogeneity. Preoperative chemotherapy was associated with fewer adverse effects. Pathological complete response is associated with better survival than residual disease (HR, 0.48; 95% CI, 0.33 to 0.69; p, < 10-4). AUTHORS' CONCLUSIONS: This review suggests safe application of preoperative chemotherapy in the treatment of women with early stage breast cancer in order to down-stage surgical requirement, to evaluate chemosensitivity and to facilitate translational research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Research works printed but not linked: 29
- Mauriac, 1999, Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS), Annals of Oncology, 10, 47, 10.1023/A:1008337009350 · doi:10.1023/a:1008337009350
- Gianni, 2005, European cooperative trial in operable breast cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF), Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 23, Abstract 513
- Forouhi, 1995, Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer, British Journal of Surgery, 82, 79, 10.1002/bjs.1800820127 · doi:10.1002/bjs.1800820127
- Scholl, 1991, Neoadjuvant chemotherapy in operable breast cancer, European Journal of Cancer, 27, 1668, 10.1016/0277-5379(91)90442-G · doi:10.1016/0277-5379(91)90442-g
- Enomoto K Ikeda T Matsui A Kitajima M Koh J Neoadjuvant therapy in stage II with T>=4CM and stage III breast cancer 6th International Conference Adjuvant therapy for Primary Breast Cancer St Gallen 1998 P73 · doi:10.1016/s0959-8049(97)89290-8
- Ostapenko V Pipiriene T Valuckas K Primary chemotherapy in conservative treatment of stage II breast cancer In 6th International Conference Adjuvant therapy for Primary Breast Cancer St Gallen 1998 Abstract P78 · doi:10.1016/s0959-8049(97)89295-7
- Gazet, 2001, Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy, Annals of Oncology, 12, 685, 10.1023/A:1011115107615 · doi:10.1023/a:1011115107615
- Makris, 1998, A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer, Annals of Oncology, 9, 1179, 10.1023/A:1008400706949 · doi:10.1023/a:1008400706949
- Semiglazov, 1994, Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer, Annals of Oncology, 5, 591, 10.1093/oxfordjournals.annonc.a058929 · doi:10.1093/oxfordjournals.annonc.a058929
- Cowan, 2003, Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial, Annals of Surgical Oncology, 10, 635, 10.1245/ASO.2003.12.008 · doi:10.1245/aso.2003.12.008
- Deo, 2003, Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0), Journal of Surgical Oncology, 84, 192, 10.1002/jso.10323 · doi:10.1002/jso.10323
- Hyams, 1993, An institutional experience with preoperative systematic chemotherapy in early stage breast cancer, Breast Cancer Research & Treatment, 27, 147 (Abstract 6
- Shao, 1999, Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis, Breast Cancer Research and Treatment, 53, 263, 10.1023/A:1006194921139 · doi:10.1023/a:1006194921139
- Stauffer, 1993, Preoperative versus postoperative adjuvant chemotherapy in early operable breast cancer, Breast Cancer Research & Treatment, 27, 148 (Abstract 1
- Felici, 2005, Taxanes as neoadjuvant chemotherapy for breast cancer: Pooled-analysis of 3120 patients enrolled in 10 randomized trials, J Clin Oncol ASCO Annual Meeting Proceedings, 16S, 682
- Fisher, 1989, A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors, New England Journal of Medicine, 320, 473, 10.1056/NEJM198902233200801 · doi:10.1056/nejm198902233200801
- Fisher, 1995, Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer, J Clin Oncol, 13, 537, 10.1200/JCO.1995.13.3.537 · doi:10.1200/jco.1995.13.3.537
- Fredriksson, 2003, Risk factors for local recurrence after breast-conserving surgery, Br J Surg, 90, 1093, 10.1002/bjs.4206 · doi:10.1002/bjs.4206
- Haagensen, 1943, Carcinoma of the breast. Criteria of inoperability, The American surgeon, 118, 859
- Haagensen, 1943, Carcinoma of the breast. Criteria of inoperability, The American surgeon, 118, 1032
- Hortobagyi, 1983, Multimodal treatment of locoregionally advanced breast cancer, Cancer, 51, 763, 10.1002/1097-0142(19830301)51:5<763::AID-CNCR2820510502>3.0.CO;2-C · doi:10.1002/1097-0142(19830301)51:5<763::aid-cncr2820510502>3.0.co;2-c
- Hortobagyi, 1997, Textbook of Breast Cancer: A Clinical Guide to Therapy, 155
- Jacquillat, 1989, Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients, Recent Results in Cancer Research, 115, 36, 10.1007/978-3-642-83337-3_6 · doi:10.1007/978-3-642-83337-3_6
- Perloff, 1982, Chemotherapy before and after mastectomy in stage III breast cancer, Archives of surgery, 117, 879, 10.1001/archsurg.1982.01380310005002 · doi:10.1001/archsurg.1982.01380310005002
- Segel, 1988, Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy, Radiology, 169, 49, 10.1148/radiology.169.1.3420282 · doi:10.1148/radiology.169.1.3420282
- Sharkey, 1996, Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma, Mod Pathol, 9, 893
- Veronesi, 1995, Conservation surgery after primary chemotherapy in large carcinomas of the breast, Ann Surg, 222, 612, 10.1097/00000658-199511000-00002 · doi:10.1097/00000658-199511000-00002
- Vinnicombe, 1996, Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation, Radiology, 198, 333, 10.1148/radiology.198.2.8596827 · doi:10.1148/radiology.198.2.8596827
- Wolff, 2000, Primary systemic therapy in operable breast cancer, J Clin Oncol, 18, 1558, 10.1200/JCO.2000.18.7.1558 · doi:10.1200/jco.2000.18.7.1558
Cited by
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Spring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., Smith, B. L., Alexander, B., Moy, B., Isakoff, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3492 · Cited by 938
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.023 · Cited by 548
Metadata
- Authors
- van der Hage, J. H., van de Velde, C. J., Mieog, S. J., & Charehbili, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2007-04-18
- Volume
- 2021
- Issue
- 5
- Pages
- CD005002-CD005002
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2144713193
- Cited by
- 407
- References
- 53
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preoperative chemotherapy for women with operable breast cancer. https://app.cochat.ai/papers/10.1002/14651858.cd005002.pub2
- The paper
- van der Hage, J. H., van de Velde, C. J., Mieog, S. J., & Charehbili, A. (2007). Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005002.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.